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we could rarely choose one member of a drug class over another in
order to reduce the risk of adverse interactions. But for many drug
classes, including the statins, we do have sufficient information to
choose members of the class that will reduce the drug interaction
risk in specific patients. To blur these differences is to put patients
at greater risk of a preventable adverse outcome.
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Efficacy of Simvastatin and
Ezetimibe in Treating Hypercholesterolemia
In a recent editorial published in JACC, Dr. Sacks summarized the
efficacy of co-administration of simvastatin and ezetimibe, a novel
cholesterol absorption inhibitor with a mechanism of action that is
complementary to statins (1,2). I appreciate the opportunity to
provide some additional data, likely not available at the time Dr.
Sacks drafted his editorial, to clarify some of the estimates
provided by Dr. Sacks (2).
Dr. Sacks took a hypothetical patient, with a pretreatment low
density lipoprotein cholesterol (LDL-C) level of 190 mg/dl, and
calculated LDL-C reductions and relative risk reduction (RRR)
estimates for simvastatin alone and simvastatin/ezetimibe co-
administration. It should be pointed out that the calculated LDL
reductions and RRR estimates for simvastatin alone and simvasta-
tin/ezetimibe in the editorial are actually too low and underesti-
mate the benefit of using ezetimibe with a statin compared to a
statin alone. This is due to the iterative use of the estimated 6%
reduction of LDL-C per doubling of simvastatin relative to
LDL-C values that were already reduced by simvastatin treatment.
The “6% rule” for incremental LDL-C lowering with doubling of
statin dose applies to the estimated reduction calculated relative to
the pre-statin LDL-C baseline (in this case, 190 mg/dl). The
correct sequence of values, therefore, would be as follows: 20 mg
simvastatin results in LDL-C of 125 mg/dl (34% reduction from
the base of 190 mg/dl); 40 mg simvastatin results in LDL-C of
114 mg/dl (40% reduction from 190 mg/dl); and 80 mg simvasta-
tin results in LDL-C of 102 mg/dl (46% reduction from 190
mg/dl). The RRR values would similarly decrease.
The same issue applies with respect to the calculation of
anticipated incremental lowering based on addition of ezetimibe.
Assuming a 14% reduction with ezetimibe, when ezetimibe is
added to the hypothetical patient already on 20 mg of simvastatin
with an LDL-C of 125 mg/dl, the reduction of LDL-C by 14%
(of 190, not 125 mg/dl) would result in a further decrease in
LDL-C of 26.6 mg/dl, bringing the patient to below the goal of
100 mg/dl without additional simvastatin titration.
The estimated efficacy from the above analysis is highly consis-
tent with the reported 27% reduction in LDL-C relative to
baseline (24% relative to placebo) observed when ezetimibe was
added to ongoing simvastatin therapy (3). The data from the
clinical trials of initiation of ezetimibe with both simvastatin and
atorvastatin indicate that 10 mg of ezetimibe added to either statin
produces incremental LDL-C lowering similar to that produced by
80 mg of the corresponding statin, an additional reduction that
would require an 8-fold increase in statin dosage to be achieved by
titration (4).
Dr. Sacks makes clearly important points about balancing
benefit and potential harm, including the fact that statin-related
adverse effects are dose dependent and occur more commonly at
the highest doses (5). Although the long-term safety experience
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with ezetimibe is more limited, the profile to date is very
encouraging, particularly with respect to the lack of any incremen-
tal risk with respect to the most worrisome statin-related side
effects, namely myopathy and rhabdomyolysis. Thus, considering
the large numbers of patients not at NCEP ATP III therapeutic
goals as well as the well-recognized reluctance of many physicians
to titrate, I believe that co-administration of ezetimibe with
low-dose statins provides a valuable new option for treatment of
hypercholesterolemia.
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REPLY
I thank Dr. Davidson for clarifying some of the estimates for low
density lipoprotein (LDL) reduction that I computed for statin
and ezetimibe doses (1). Although we do have treatment goals for
LDL cholesterol (LDL-C), it is worth emphasizing that it is risk
reduction that is the ultimate goal. The additional risk reduction
expected from two doublings of a statin dose or from ezetimibe
remains modest in typical patients, about 15% for a patient with a
pretreatment LDL-C of 190 mg/dl, and 12% when the pretreat-
ment LDL-C is 140 mg/dl. This reflects the modest efficacy of
ezetimibe, a 14% lowering of LDL-C shown in Dr. Davidson’s
excellent study (2), and of two doublings of statin doses. This
magnitude is consistent with much of the literature on the drug.
The added value in terms of risk reduction appears rather modest
and needs to be balanced against the cost, lack of long-term
outcome data, and need for other medications, particularly in older
patients.
My perspective is that the benefits and safety of statin therapy
are very well established, and I favor its use across the approved
dose ranges. I am finding ezetimibe useful in combination with 40
mg or 80 mg of a statin in patients with moderate to severe
hypercholesterolemia for whom more substantial risk reduction
should occur from additional LDL reduction. I am much less
convinced that adverse effects of statin therapy truly occur in more
than a very few patients. I base this on results of trials that compare
adverse effects reported during statin therapy with those during
placebo treatment in tens of thousands of patients (3,4). Myalgia is
a common feature of the human condition, inexorably increasing
with aging. When patients complain of myalgias while taking
statins, it is important to ensure that it fits the clinical features of
statin-myopathy, following the accepted guidelines for this diag-
nosis (5). Whether ezetimibe or other nonstatin LDL-lowering
drugs like colesevelam offer a useful alternative in “statin intoler-
ant” patients remains to be determined.
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